Ping An Biomedical Co., Ltd.
PASWNasdaq
$0.15
↓ -0.8%Jul 17 close · end-of-day
Price
1Y↓ -95.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.7M
Enterprise Value
$3.9M
P/E
—
P/S
0.6
P/B
0.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$4.8M
Net Income (TTM)
-$1.8M
Free Cash Flow (TTM)
—
Gross Margin
2.8%
Operating Margin
-43.0%
Net Margin
-37.6%
ROE
-28.4%
ROIC
-21.5%
Debt / Equity
0.2
Net Cash
-$1.2M
Return 1Y
—
Company profile
We are a holding company incorporated in the Cayman Islands with operations conducted by our PRC subsidiary New Brand, which is headquartered in Shanghai, the PRC. Our principal offices are located at 22/F, China United Plaza, 1002-1008 Tai Nan West Street, Cheung Sha Wan, Kowloon, Hong Kong. Our registered office in the Cayman Islands is located at the Conyers Trust Company (Cayman) Limited, Cricket Square, Hutchins Drive, PO Box 2681, Grand Cayman, KY1-1111, Cayman Islands. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor New York, NY.
- CEO
- Suqin Li
- Sector
- Manufacturing
- Industry
- Apparel
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | $4.8M |
| Gross profit | — | — | $133,376.00 |
| Operating income | — | — | -$2.1M |
| Net income | — | — | -$1.8M |
| Diluted EPS | — | — | -$0.10 |
| Operating cash flow | — | — | -$902,902.00 |
| Free cash flow | — | — | — |
| Gross margin | — | — | 2.8% |
| Operating margin | — | — | -43.1% |
| Net margin | — | — | -37.6% |
No quarterly data.
Company news
Jan 9, 2026
- 192d agoPing An Biomedical Co., Ltd Announces Strategic Investment in Future Biotechnology Group to Advance Collaborative Development of the Biopharmaceutical Industryfinance.yahoo.com
- 192d agoPing An Biomedical Co., Ltd. Receives Strategic Investment from Leading Industry Capital, Accelerating Growth in Biopharmaceutical Innovationfinance.yahoo.com
Sep 12, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.